Certain Common Stock of bluebird bio, Inc. are subject to a Lock-Up Agreement Ending on 26-JAN-2018.
January 25, 2018
Share
Certain Common Stock of bluebird bio, Inc. are subject to a Lock-Up Agreement Ending on 26-JAN-2018. These Common Stock will be under lockup for 45 days starting from 12-DEC-2017 to 26-JAN-2018.
Details:
Shares and securities convertible into or exchangeable for shares held by the directors and executive officers of the company will be under lock up for a period of 45 days after the date of this prospectus supplement.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
BLUEBIRD BIO, INC. 
